Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the launch of a novel ...

Quest Diagnostics debuts a new blood test for myeloma MRD, offering NGS-level sensitivity and a less invasive alternative to ...

Quest expects the new blood test will support response monitoring in clinical trials.

Quest Diagnostics has rolled out an ultrasensitive blood test to monitor multiple myeloma treatment, potentially sparing patients from more invasive and costly bone marrow aspirations. | Quest ...